by City of Hope National Medical Center Type II interferon (IFNy), a substance produced by immune cells, disrupts the leukemia stem cells’ ability to divide and spread cancer. However, IFNy also stimulates CD38, a protein that suppresses the immune cells’ ability to mount a response against infection. To overcome this challenge, City of Hope researchers designed...
by Josep Carreras Leukaemia Research Institute Credit: Cancer Research Communications (2024). DOI: 10.1158/2767-9764.CRC-23-0389Alterations in the chemical modifications that control gene expression, known as epigenetics, have proven to be one of the most characteristic properties of all human tumors. This realization has generated the development of intense pharmacological research to find drugs that act at this level...
Symptoms of leukemia can include skin-related issues, such as a rash or bruising. Petechiae and purpura can be the first sign of leukemia a person may notice. When a person has leukemia, their body produces too many white blood cells. As they continue to grow in number, they crowd out the other cells in the...
by University of Texas at El Paso Renato Aguilera, Ph.D., a professor in the Department of Biological Sciences at The University of Texas at El Paso, is the principal investigator on a project that identified a novel pharmaceutical compound that successfully kills leukemia and lymphoma cancer cells, potentially paving the way for new forms of therapy....
by Kathrin Kottke, University of Münster Credit: Blood Advances (2023). DOI: 10.1182/bloodadvances.2023011076Decisions on treatment for patients with acute myeloid leukemia (AML)—a highly aggressive form of leukemia—are based, among other things, on a series of certain genetic features of the disease; but at the time when a diagnosis is made, this information is not available. Evidence of...
by Elana Gotkine For patients with acute myeloid leukemia (AML), immediate allogeneic hematopoietic stem cell transplantation (HCT) after primary induction failure (PIF) offers long-term survival benefit, according to a study published online Dec. 10 in the Blood Cancer Journal. Miriam Mozaffari Jovein, M.D., from the University of Freiburg in Germany, and colleagues retrospectively assessed long-term...
by University of Birmingham Credit: Cell Reports (2023). DOI: 10.1016/j.celrep.2023.113568 A highly aggressive common form of leukemia which is activated by mutations in signaling molecules is maintained by a web of regulatory proteins downstream of these signals. New research published in Cell Reports shows that a complex network of interacting genes activated by this altered signaling...
by Goethe University Frankfurt am Main AML xenografts are susceptible to transient LNP/miR-193b treatment in vitro. A The absolute number of human AML PDX cells after treatment with single dose of 4 µg/ml LNPs. B Percentage of apoptotic cells (Annexin V+) on day 2 post treatment. A, B Data are represented as the mean ± standard deviation of three...
Randy Dotinga For patients with acute myeloid leukemia (AML), especially those who are older or have relapsed/refractory disease, standard chemotherapy treatments often fail to change their poor clinical trajectories. These days, however, a new era of targeted therapy is improving prognoses somewhat — and raising hopes that even bigger advancements are on the horizon. “We...
by QIMR Berghofer Integrative analysis of samples from patients with AML. a, Unsupervised hierarchical clustering analysis on the expression of 300 transcripts with the greatest variance-to-mean ratios among 30 individual AMLs from our repository that can successfully generate AML PDX. MLD, multi-lineage dysplasia; MDS, myelodysplastic syndromes; MLL, mixed-lineage leukemia; NOS, not otherwise specified. b, Key...
